TD Cowen analyst William Katz maintained a Hold rating on Artisan Partners (APAM – Research Report) today and set a price target of $46.00. The ...

TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...

TD Cowen analyst William Katz maintained a Hold rating on Carlyle Group (CG – Research Report) today and set a price target of $54.00. The ...

China-based GDS Holdings (GDS) is surging 6% after investment bank TD Cowen raised its price target on the shares. The ...

CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

TD Cowen had upgraded Merck in early 2024 based on confidence in Keytruda and Gardasil’s performance, a lack of binary risks, and an attractive valuation. However, setbacks in Gardasil’s China sales ...

TD Cowen analysts made adjustments to the stock of Fidelity National Information Services (NYSE:FIS), reducing the price target to $81 from the previous $87 while maintaining a Hold rating on the ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

News of a significant price-target boost from an analyst tracking GDS Holdings ( GDS 7.20%) was the main catalyst behind the ...